Rituximab in Routine Care Of severe Active Rheumatoid Arthritis : A prospective, Non-interventional Study In Germany

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2018 Oct 3

PMID 30276727

Citations 3

Authors

A Krause

P M Aries

S Berger

C Fiehn

H Kellner

H-M Lorenz

L Meier

G A Muller

U Muller-Ladner

A Schwarting

H-P Tony

M A Peters

J Wendler

Affiliations

Soon will be listed here.

Abstract

Objective: To assess safety, effectiveness and onset of effect of rituximab (RTX) in routine clinical treatment of severe, active rheumatoid arthritis (RA).

Methods: Prospective, multi-centre, non-interventional study in rheumatological outpatient clinics or private practices in Germany. RTX-naïve adult patients were to receive RTX according to marketing authorisation and at their physician's discretion. Also according to their physician's discretion, patients could receive a second cycle of RTX (re-treatment = treatment continuation). Major outcome was the change in Disease Activity Score based on 28-joints count and erythrocyte sedimentation rate (DAS28-ESR) over 24 weeks and during 6 months of re-treatment.

Results: Overall, 1653 patients received at least one cycle RTX; 99.2% of these had received disease-modifying antirheumatic drugs (DMARD) pre-treatment and 75.5% anti-tumor necrosis factor(TNF)‑α pre-treatment. After a mean interval of 8.0 months, 820 patients received RTX re-treatment. Mean DAS28-ESR decreased from 5.3 at baseline to 3.8 after 24 weeks (-1.5 [95% confidence interval, CI: -1.6; -1.4]), and from 4.1 at start of cycle 2 to 3.5 at study end (change from baseline: -1.8 [95% CI: -2.0; -1.7]). Improvements in DAS28-ESR and Health Assessment Questionnaire (HAQ) score occurred mainly during the first 12 weeks of RTX treatment, with further DAS28-ESR improvement until week 24 or month 6 of re-treatment. Improvements in DAS28-ESR and EULAR responses were more pronounced in seropositive patients. RF was a predictor of DAS28-ESR change to study end. Safety analysis showed the established profile of RTX.

Conclusion: RTX was safe and effective in a real-life setting with rapid and sustained improvement in RA signs and symptoms.

Citing Articles

Long-term drug effectiveness and survival for reference rituximab in rheumatoid arthritis patients in an ordinary outpatient clinic.

Losinska K, Wilk M, Pripp A, Korkosz M, Haugeberg G Sci Rep. 2022; 12(1):8283.

PMID: 35585215 PMC: 9117312. DOI: 10.1038/s41598-022-12271-9.

Low-dose rituximab protocol in rheumatoid arthritis-outcome and economic impact.

Chandramohan P, Jain A, Antony G, Krishnan N, Shenoy P Rheumatol Adv Pract. 2021; 5(1):rkaa077.

PMID: 33605940 PMC: 7878847. DOI: 10.1093/rap/rkaa077.

Early restoration of immune and vascular phenotypes in systemic lupus erythematosus and rheumatoid arthritis patients after B cell depletion.

Perez-Sanchez C, Cecchi I, Barbarroja N, Patino-Trives A, Luque-Tevar M, Perez-Sanchez L J Cell Mol Med. 2019; 23(9):6308-6318.

PMID: 31347786 PMC: 6714224. DOI: 10.1111/jcmm.14517.

References

Valleala H, Korpela M, Mottonen T, Hienonen-Kempas T, Kauppi M, Hannonen P . Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol. 2009; 38(5):323-7. DOI: 10.1080/03009740902946355. View

Smolen J, Keystone E, Emery P, Breedveld F, Betteridge N, Burmester G . Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 66(2):143-50. PMC: 1798500. DOI: 10.1136/ard.2006.061002. View

Kekow J, Mueller-Ladner U, Schulze-Koops H . Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics. 2012; 6:191-9. PMC: 3402045. DOI: 10.2147/BTT.S32244. View

Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X . B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011; 63(4):933-8. DOI: 10.1002/art.30233. View

Wendler J, Burmester G, Sorensen H, Krause A, Richter C, Tony H . Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther. 2014; 16(2):R80. PMC: 4060207. DOI: 10.1186/ar4521. View

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M . Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009; 48(12):1557-9. DOI: 10.1093/rheumatology/kep314. View

Vander Cruyssen B, Durez P, Westhovens R, Kaiser M, Hoffman I, De Keyser F . The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther. 2010; 12(5):R169. PMC: 2990996. DOI: 10.1186/ar3129. View

Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M . Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken). 2012; 65(4):648-52. DOI: 10.1002/acr.21865. View

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U . Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2011; 71(3):374-7. DOI: 10.1136/annrheumdis-2011-200003. View

10.

Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont-Creteur C, Legrand J . Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine. 2011; 79(3):281-4. DOI: 10.1016/j.jbspin.2011.05.002. View

11.

Harrold L, Reed G, Shewade A, Magner R, Saunders K, John A . Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015; 42(7):1090-8. DOI: 10.3899/jrheum.141043. View

12.

Vassilopoulos D, Delicha E, Settas L, Andrianakos A, Aslanidis S, Boura P . Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clin Exp Rheumatol. 2016; 34(5):893-900. View

13.

Soliman M, Hyrich K, Lunt M, Watson K, Symmons D, Ashcroft D . Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol. 2011; 39(2):240-6. DOI: 10.3899/jrheum.110610. View

14.

Isaacs J, Cohen S, Emery P, Tak P, Wang J, Lei G . Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2012; 72(3):329-36. DOI: 10.1136/annrheumdis-2011-201117. View

15.

Emery P, Deodhar A, Rigby W, Isaacs J, Combe B, Racewicz A . Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating.... Ann Rheum Dis. 2010; 69(9):1629-35. PMC: 2938895. DOI: 10.1136/ard.2009.119933. View

16.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland M, Tarp U . Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther. 2016; 18:50. PMC: 4756505. DOI: 10.1186/s13075-016-0951-z. View

17.

Emery P, Mease P, Rubbert-Roth A, Curtis J, Muller-Ladner U, Gaylis N . Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford). 2011; 50(12):2223-32. PMC: 3222846. DOI: 10.1093/rheumatology/ker253. View

18.

Emery P, Gottenberg J, Rubbert-Roth A, Sarzi-Puttini P, Choquette D, Taboada V . Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014; 74(6):979-84. PMC: 4431330. DOI: 10.1136/annrheumdis-2013-203993. View

19.

Cohen S, Emery P, Greenwald M, Dougados M, Furie R, Genovese M . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54(9):2793-806. DOI: 10.1002/art.22025. View

20.

Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J . Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register. Arthritis Care Res (Hoboken). 2014; 66(11):1627-33. PMC: 4282041. DOI: 10.1002/acr.22327. View